ABL1(9q34) Gene Break Apart Probe Detection Kit (IVD)

ABL1(9q34) Gene Break Apart Probe Detection Kit (IVD)

ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase) is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.